Aquestive Therapeutics Inc (AQST)
3.10
-0.18
(-5.49%)
USD |
NASDAQ |
May 17, 16:00
3.10
0.00 (0.00%)
After-Hours: 20:00
Aquestive Therapeutics Revenue (Quarterly): 12.05M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 12.05M |
| December 31, 2023 | 13.21M |
| September 30, 2023 | 13.00M |
| June 30, 2023 | 13.24M |
| March 31, 2023 | 11.13M |
| December 31, 2022 | 10.68M |
| September 30, 2022 | 11.46M |
| June 30, 2022 | 13.26M |
| March 31, 2022 | 12.27M |
| December 31, 2021 | 11.08M |
| September 30, 2021 | 13.29M |
| June 30, 2021 | 15.34M |
| March 31, 2021 | 11.12M |
| December 31, 2020 | 7.149M |
| September 30, 2020 | 8.26M |
| Date | Value |
|---|---|
| June 30, 2020 | 21.68M |
| March 31, 2020 | 8.765M |
| December 31, 2019 | 16.42M |
| September 30, 2019 | 12.42M |
| June 30, 2019 | 11.13M |
| March 31, 2019 | 12.64M |
| December 31, 2018 | 16.82M |
| September 30, 2018 | 13.27M |
| June 30, 2018 | 13.93M |
| March 31, 2018 | 23.41M |
| December 31, 2017 | 12.20M |
| September 30, 2017 | 27.15M |
| June 30, 2017 | 11.14M |
| March 31, 2017 | 16.44M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
7.149M
Minimum
Dec 2020
21.68M
Maximum
Jun 2020
12.35M
Average
12.16M
Median
Revenue (Quarterly) Benchmarks
| Lifecore Biomedical Inc | 31.55M |
| Harrow Inc | 34.59M |
| Akebia Therapeutics Inc | 32.61M |
| 89bio Inc | -- |
| Humacyte Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -12.83M |
| Total Expenses (Quarterly) | 21.01M |
| EPS Diluted (Quarterly) | -0.17 |
| Enterprise Value | 216.71M |
| Gross Profit Margin (Quarterly) | 63.59% |
| Profit Margin (Quarterly) | -106.4% |
| Earnings Yield | -13.96% |
| Normalized Earnings Yield | -13.57 |